InvestorsHub Logo
Followers 608
Posts 42247
Boards Moderated 6
Alias Born 01/10/2004

Re: GNOTE post# 1220

Monday, 03/23/2009 12:57:05 PM

Monday, March 23, 2009 12:57:05 PM

Post# of 7234
Cell Therapeutics Announces Filing of Form 10-K

Monday , March 23, 2009 12:37ET

http://www.knobias.com/story.htm?eid=3.1.506dccc33a238a0fad1bf9368edf0ec06b7d1e5e954310e267ad0da0473a2109

SEATTLE, March 23 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has filed its annual report on Form 10-K for the year ended December 31, 2008. This filing is available for review on CTI's website at http://www.CellTherapeutics.com, or on the Securities and Exchange Commission's web site at www.sec.gov.

As required under NASDAQ Marketplace Rule 4350(b)(1)(B), CTI also announced that its independent auditor's report included in the annual report on Form 10-K contains a "going concern" qualification.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

SOURCE Cell Therapeutics, Inc.

Contacts:

media
Dan Eramian
206-272-4343
cell
206-854-1200
media@ctiseattle.com

investors, Ed Bell
206-282-7100
Lindsey Jesch Logan
206-272-4347
fax
206-272-4434
invest@ctiseattle.com

all for Cell Therapeutics, Inc.


Public Companies Associated with this story:
CTIC

Knobias Subject Codes Associated with this story:
Earnings Release Period Filing

Content provided by PR Newswire Copyright © 2009
Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/story.htm?eid=3.1.506dccc33a238a0fad1bf9368edf0ec06b7d1e5e954310e267ad0da0473a2109

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.

This Is only my opinion posted here please due not buy or sale a stock base on my opinion. For practice or educational learning purpose only.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.